A new regulatory decision in Europe has approved the drug Dupixent for adults with uncontrolled chronic obstructive pulmonary disorder (COPD) characterized by elevated levels of eosinophils. The drug, developed by Sanofi and Regeneron Pharmaceuticals, targets type 2 inflammation in COPD without suppressing the immune system. The European approval was based on positive results from two Phase 3 clinical trials showing a reduction in exacerbations, improved lung function, and quality of life. Despite doubts in the past, Dupixent has shown promise in treating COPD, marking a significant advancement in the field of respiratory research. The FDA is currently reviewing the drug application for COPD with a decision expected in September.
Source link
Sanofi & Regeneron Drug Dupixent Gets EMA Approval as the First Biologic COPD Med
